Introduction {#sec1-1}
============

The presence of α-synuclein aggregates is a characteristic of many neurodegenerative diseases, including Parkinson\'s disease (PD) and Lewy body dementia (Kalia et al., 2013; Tanik et al., 2013). Accumulating evidence shows that α-synuclein misfolding, aggregation and abnormal degradation cause dopaminergic neuron death (Bartels et al., 2011; Gadad et al., 2011; Cremades et al., 2012). This process underlies PD pathogenesis (Venda et al., 2010; Kalia et al., 2013; Ryan et al., 2014). Although monoubiquitinated and polyubiquitinated α-synuclein are present in Lewy bodies, the regulation of α-synuclein ubiquitination and its role in the formation of Lewy bodies are not fully understood (Engelender, 2008; Lee et al., 2008). Recent studies show that the E3 ubiquitin ligase seven in absentia homolog 1 (SIAH-1) mediates α-synuclein monoubiquitination (Engelender, 2008; Lee et al., 2008). SIAH-1 also plays a key role in Lewy body formation and pathogenesis in PD, contributing to α-synuclein aggregation and intracellular inclusion formation. The intracellular inclusions and aggregates cannot be cleared by the ubiquitin-proteasome pathway, and must therefore rely on the autophagy degradation pathway (Engelender, 2008; Lee et al., 2008).

Despite the data linking SIAH-1 to α-synuclein aggregation and degradation, the function of SIAH-1 in the autophagy-lysosomal pathway remains unknown. Furthermore, it is not clear whether SIAH-1-mediated ubiquitination directs α-synuclein to the ubiquitin-proteasome pathway or the autophagy pathway. SIAH-1 may activate or downregulate autophagy *via* the p53 pathway, thereby promoting or inhibiting the degradation of α-synuclein. To clarify the role of SIAH-1 in α-synuclein degradation, we induced autophagy and inhibited SIAH-1 function using an anti-SIAH-1 antibody. We then examined the effects on SIAH-1 activity, p53 expression and on the ubiquitin proteasome pathway and the autophagy-lysosomal degradation pathway.

Materials and Methods {#sec1-2}
=====================

Cell culture and treatments {#sec2-1}
---------------------------

The rat pheochromocytoma (PC12) cell line was purchased from Shanghai Institute of Cell Biology, Chinese Academy of Sciences (Shanghai, China). All cell lines were maintained in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum (C11995; Life Technologies, Carlsbad, CA, USA). For experiments, cells were seeded in culture flasks, or 24 or 96-well plates until 60--70% confluence. Cells were divided into six groups. In the control group, the normal growth of cells was observed. In the rapamycin (RAPA) group, cells were treated with 0.2 μg/mL RAPA (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 24 hours. In the anti-SIAH-1 group, cells were treated with 4 μg/mL anti-SIAH-1 antibody (Santa Cruz Biotechnology) for 24 hours. In the 1-methyl-4-phenylpyridinium (MPP^+^) group, cells were treated with 0.5 mM MPP^+^ (Santa Cruz Biotechnology) for 24 hours. In the MPP^+^ RAPA group, cells were treated with MPP^+^ for 24 hours then RAPA for 24 hours. In the MPP^+^ anti-SIAH-1 group, cells were treated with MPP^+^ for 24 hours then anti-SIAH-1 antibody for 24 hours.

3-(4,5-Cimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay for cell viability {#sec2-2}
--------------------------------------------------------------------------------------------

Cells were cultured in 96-well plates with RPMI-1640 medium containing 10% fetal bovine serum at a density of 1 × 10^5^/mL, in a volume of 200 μL/well. Cells in the exponential phase of growth were incubated with MPP^+^, RAPA and SIAH-1 antibody for 24 hours. The culture medium was refreshed, and 20 μL MTT solution (final concentration of 0.5 mg/mL) was added to each well. Cells were incubated at 37°C for an additional 4 hours in the dark. After incubation, the medium containing MTT was removed, and 150 μL dimethyl sulfoxide was added to each well to dissolve the formazan dye crystals on a shaker for 15 minutes. The optical density was measured at 492 nm with a microplate reader (Model 680; Bio-Rad, CA, USA). Cell viability was expressed as a percentage of the value in the control group.

Western blot analysis {#sec2-3}
---------------------

Western blot analysis was performed as previously described by our group (Cai et al., 2009). Cells were lysed and sonicated in lysis buffer. After electrophoresis, samples were transferred onto a polyvinylidene difluoride membrane (Millipore, Temecula, CA, USA), and then immunoblotted with the following antibodies: goat polyclonal anti-SIAH-1 (1:100; sc-5505; Santa Cruz Biotechnology), rabbit polyclonal anti-α-synuclein (1:1,000; 2642; Cell Signaling Technology, Danvers, MA, USA), rabbit polyclonal anti-light chain 3 (LC3) (1:1,000; ab62721; Abcam, Cambridge, MA, USA), rabbit polyclonal anti-E1 (1:1,000; 4891S; Cell Signaling Technology), rabbit polyclonal anti-P53 (1:1,000; 2642; Cell Signaling Technology), and mouse monoclonal β-actin (1:1,000; A3854; Sigma-Aldrich, St Louis, MO, USA). Subsequently, the following horseradish peroxidase-conjugated secondary antibodies were added: polyclonal goat anti-rabbit secondary antibody for LC3, α-synuclein and E1; polyclonal donkey anti-goat secondary antibody for SIAH-1; and polyclonal goat anti-mouse secondary antibody for β-actin (1:1,000; Beyotime Biotechnology, Jiangsu, China). Images were captured using the Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln, NE, USA), and band intensities were calculated by densitometric analysis using Image J software (NIH, Bethesda, MD, USA).

Semi-quantitative analysis of mRNA by reverse transcription (RT)-PCR {#sec2-4}
--------------------------------------------------------------------

Total RNA was extracted from PC12 cells using TRIzol (Life Technologies). First-strand cDNA was synthesized using PrimeScript RT Enzyme Mix I (RR037A; Takara, Otsu, Japan). Primer pairs for the amplification of cDNA for LC3, α-synuclein, SIAH-1 and β-actin were designed ([**Table 1**](#T1){ref-type="table"}). cDNA amplification was performed using DyNAmo SYBR green qPCR kits (Finnzymes Oy, Espoo, Finland). Amplification was performed using an iCycler iQ Multicolor Real Time PCR Detection System (Bio-Rad, Hercules, CA, USA). The expression levels of LC3, SIAH-1 and α-synuclein were normalized to that of β-actin.

###### 

Primer pairs for the amplification of cDNA transcripts

![](NRR-10-1286-g001)

Immunofluorescence microscopy {#sec2-5}
-----------------------------

PC12 cells were seeded onto non-coated 12-mm coverslips and treated with MPP^+^ (0.5 mM, 24-hour exposure) and goat polyclonal SIAH-1 antibody (4 μg/mL, 24 hours), and then fixed in ice-cold 4% paraformaldehyde for 15 minutes. The cells were incubated with rabbit polyclonal anti-LC3 antibody (1:250), goat polyclonal anti-SIAH-1 antibody (1:500) or rabbit polyclonal anti-α-synuclein antibody (1:250) for 1.5 hours at 37°C. Cells were then treated with polyclonal mouse anti-rabbit secondary antibody for LC3 and α-synuclein or polyclonal mouse anti-goat secondary antibody for SIAH-1 (1:1,000; Beyotime Biotechnology) for 1 hour at 37°C. Thereafter, cells were stained with 4′,6-diamidino-2-phenylindole (0.3 μg/mL) for 15 minutes, and examined with a laser scanning confocal microscope (TCS SP2 CLSM; Leica, Wetzlar, Germany). Images were collected and processed using the imaging software provided with the Leica TCS system.

Statistical analysis {#sec2-6}
--------------------

All experiments were performed in triplicate, and the results are presented as the mean ± SD. Statistical analysis was performed using SPSS 12.0 software (SPSS, Chicago, IL, USA). Multiple group comparisons were performed using one-way analysis of variance and Fisher\'s least significant difference test (equal variances assumed). A value of *P* \< 0.05 was considered statistically significant.

Results {#sec1-3}
=======

SIAH inhibition increased cell viability {#sec2-7}
----------------------------------------

We assessed PC12 cell viability after a 24-hour treatment with RAPA (used to induce autophagy) and SIAH-1 antibody. We found no significant effect on viability under normal growth conditions (*P* \> 0.05). As expected, MPP^+^-treated cells showed reduced viability. RAPA and SIAH-1 antibody each significantly increased viability in cells treated with MPP^+^ (*P* = 0.0008 and 0.0014, respectively). These results indicate that RAPA and SIAH-1 antibody improve viability in MPP^+^-stressed cells ([**Figure 1**](#F1){ref-type="fig"}).

![MTT assay for cell viability after treatment with MPP^+^, RAPA and SIAH-1 antibody.\
RAPA and SIAH-1 antibody treatment had no significant effect on cell viability under normal growth conditions (*P* \> 0.05). In the MPP^+^ group, RAPA and SIAH-1 antibody significantly increased cell viability (\#\#*P* \< 0.01, *vs*. MPP^+^ group; mean ± SD, *n* ≥ 6, one-way analysis of variance followed by Fisher\'s least significant difference *post hoc* test). I: Control group; II: RAPA group; III: anti-SIAH-1 group; IV: MPP^+^ group; V: MPP^+^ RAPA group; VI: MPP^+^ anti-SIAH-1 group. MTT: 3-(4,5-Cimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; MPP^+^: 1-methyl-4-phenylpyridinium; RAPA: rapamycin; SIAH-1: E3 ubiquitin ligase seven in absentia homolog 1.](NRR-10-1286-g002){#F1}

MPP^+^ increased α-synuclein expression and SIAH-1 levels {#sec2-8}
---------------------------------------------------------

MPP^+^ treatment not only increased the expression of α-synuclein (*P* \< 0.01) and E1 (*P* \< 0.01), but also that of SIAH-1 (*P* \< 0.01). We found a nonsignificant increase in LC3-II expression (*P* = 0.17) ([**Figure 2**](#F2){ref-type="fig"}). In addition, we observed significant α-synuclein aggregation and localization in the cytoplasm after MPP^+^ treatment. SIAH-1 immunofluorescence staining was significantly increased after 24 hours of MPP^+^ treatment ([**Figure 3**](#F3){ref-type="fig"}).

![Effects of SIAH-1 antibody treatment on α-synuclein and the autophagy degradation pathway in PC12 cells.\
Western blot assay for protein levels (upper panel) and statistical analysis of optical density measurements (target protein/β-actin; lower panel) in PC12 cells after treatment with MPP^+^, RAPA and SIAH-1 antibody. (A) SIAH-1 (37 kDa); (B) α-synuclein (19 kDa); (C) p53 (55 kDa); (D) LC3-II (17 kDa); (E) E1 (117 kDa). Values are represented as the mean ± SD (*n* = 5) (one-way analysis of variance followed by Fisher\'s least significant difference *post hoc* test). \#*P* \< 0.05, \#\#*P* \< 0.01, *vs*. control group (MPP^+^, RAPA and anti-SIAH-1 are "--"). \*\**P* \< 0.01, *vs*. MPP^+^ group (MPP^+^ is "+"; RAPA and anti-SIAH-1 are "--"). SIAH-1: E3 ubiquitin ligase seven in absentia homolog 1; LC3: light chain 3; MPP^+^: 1-methyl-4-phenylpyridinium; RAPA: rapamycin.](NRR-10-1286-g003){#F2}

![Change in α-synuclein and SIAH-1 in PC12 cells in response to MPP^+^.\
(A) Immunolabeling for α-synuclein (green) and SIAH-1 (red) or DAPI staining (blue) in PC12 cells. Image overlays are shown in the third column. MPP^+^ treatment caused an increase in SIAH-1 and α-synuclein fluorescence intensities (laser scanning confocal microscope; scale bars: 30 μm). (B) Quantification of fluorescence intensities of α-synuclein and SIAH-1. At least 30 cells were included for analysis from five images per group. Values are presented as the mean ± SD (*n* = 5; one-way analysis of variance followed by Fisher\'s least significant difference *post hoc* test). \*\**P* \< 0.01, *vs*. control group (normal growth of cells). SIAH-1: E3 ubiquitin ligase seven in absentia homolog 1; MPP^+^: 1-methyl-4-phenylpyridinium; DAPI: 4′,6-diamidino-2-phenylindole.](NRR-10-1286-g004){#F3}

Effects of autophagy induction on SIAH levels and α-synuclein degradation {#sec2-9}
-------------------------------------------------------------------------

Autophagy was induced by rapamycin treatment, and SIAH-1 levels and α-synuclein degradation were measured. LC3-II levels were significantly increased (*P* \< 0.01), while E1 expression was decreased (*P* \< 0.01), and SIAH-1 levels were increased (*P* \< 0.01), with no significant change in P53 or α-synuclein expression (*P* = 0.536). Additionally, LC3-II and E1 expression levels were increased in the MPP^+^ group (*P* \< 0.01), while E1 expression was reduced significantly (*P* \< 0.01). RAPA treatment significantly diminished SIAH-1 and α-synuclein levels (*P* \< 0.01; [**Figure 2**](#F2){ref-type="fig"}).

Decreasing SIAH activity reduced α-synuclein levels and inhibits the autophagy degradation pathway {#sec2-10}
--------------------------------------------------------------------------------------------------

SIAH activity was inhibited by treating cells with SIAH-1 antibody. LC3-II expression was decreased (*P* = 0.004), and E1 expression was increased significantly (*P* \< 0.01). Both p53 and α-synuclein levels decreased significantly (*P* \< 0.01). A consistent trend was found in the MPP^+^ group, where SIAH-1 levels significantly decreased after treatment with SIAH-1 antibody (*P* \< 0.01). Furthermore, LC3-II expression decreased (*P* \< 0.01) and E1 expression increased (*P* \< 0.01). Finally, p53 and α-synuclein levels decreased significantly (*P* \< 0.01; [**Figure 2**](#F2){ref-type="fig"}).

Inhibition of SIAH-1 altered SIAH-1, E1, LC3-II and α-synuclein mRNA levels {#sec2-11}
---------------------------------------------------------------------------

To confirm western blot assay results, we measured mRNA levels of SIAH-1, E1, LC3-II and α-synuclein after SIAH-1 antibody treatment. Consistent with western blot results, we observed decreased mRNA expression levels of SIAH-1, LC3-II and α-synuclein (*P* \< 0.05), and increased E1 mRNA levels (*P* = 0.0086; data not shown).

MPP^+^ treatment elevated E1 mRNA levels (*P* = 0.0302). However, α-synuclein levels increased (*P* = 0.0030). In addition, MPP^+^ treatment increased LC3-II and SIAH-1 mRNA levels (*P* \< 0.01). SIAH-1 antibody treatment reversed these trends and significantly reduced SIAH-1 transcript levels (*P* \< 0.0001). In contrast, E1 mRNA expression increased (*P* = 0.0170; data not shown).

α-Synuclein, SIAH-1 and LC3 colocalized in PC12 cells {#sec2-12}
-----------------------------------------------------

We explored the relationship between SIAH-1, α-synuclein and LC3 in the cells after SIAH-1 antibody treatment by examining their localization using immunofluorescence. Immunoreactivities of α-synuclein, SIAH-1 and LC3 decreased after SIAH-1 antibody treatment. In addition, colocalization of α-synuclein and LC3 was lost. However, α-synuclein and SIAH-1 retained their colocalization. Furthermore, α-synuclein aggregates were significantly reduced ([**Figure 4**](#F4){ref-type="fig"}).

![Colocalization of α-synuclein, SIAH-1 and microtubule-associated protein LC3 in PC12 cells after SIAH-1 antibody treatment.\
(A, C) Laser scanning confocal microscope; scale bars: 30 μm. Immunoreactivity for α-synuclein, SIAH-1 and LC3 decreased after treatment with SIAH-1 antibody, and colocalization of α-synuclein and LC3 was lost, but α-synuclein and SIAH-1 retained their colocalization. (A) Immunostaining for α-synuclein (green), microtubule-associated protein LC3 (red) and DAPI (blue). (B) Quantification of immunostaining results in A. (C) Immunostaining for α-synuclein (green), SIAH-1 (red) and DAPI (blue). (D) Quantification of immunostaining results in C. Values are presented as the mean ± SD (*n* = 5; one-way analysis of variance followed by Fisher\'s least significant difference *post hoc* test). \*\**P* \< 0.01, *vs*. control group (normal growth of cells). SIAH-1: E3 ubiquitin ligase seven in absentia homolog 1; LC3: light chain 3; DAPI: 4′,6-diamidino-2-phenylindole.](NRR-10-1286-g005){#F4}

Discussion {#sec1-4}
==========

The ubiquitin-proteasome and autophagy-lysosomal pathways are two main pathways for clearing proteins and organelles in eukaryotic cells (Jimenez-Sanchez et al., 2012; Kuang et al., 2013; Nixon, 2013). The proteasome is a barrel-shaped multi-protein complex that degrades short-lived nuclear and cytosolic proteins (Jimenez-Sanchez et al., 2012; Sadanandom et al., 2012; Gu and Enenkel, 2014). Proteasome substrates are forced to linearize and travel through the narrow cylindrical pore of the proteasome, preventing the clearance of oligomers and aggregates (Verhoef et al., 2002; Mizushima and Komatsu, 2011). The E3 ubiquitin ligase SIAH-1 monoubiquitinates α-synuclein and promotes aggregation and toxicity in cells (Rott et al., 2008, 2011; Engelender, 2012). The α-synuclein monoubiquitination leads to α-synuclein aggregation and the formation of intracellular inclusions in dopaminergic neurons (Szargel et al., 2009; Alvarez-Castelao and Castano, 2011). Therefore, we hypothesized that the inhibition of SIAH-1 would suppress α-synuclein monoubiquitination and aggregation, leading to increased levels of monomers. The monomers would then likely be selectively degraded by the ubiquitin-proteasome pathway, but not by the autophagy pathway.

Several *in vitro* studies (Kalivendi et al., 2004; Su et al., 2011; Park et al., 2014), including our previous study (Cai et al., 2009), have shown that MPP^+^ induces α-synuclein expression and aggregation. This results in symptoms similar to those in Parkinson\'s disease in experimental animals and humans (Sherer et al., 2002; Yang et al., 2009), and appear to be induced by, among others, increased levels of oxidative stress and apoptosis (Fiskum et al., 2003; Bernstein and O'Malley, 2013; Schildknecht et al., 2013). However, it is unclear how oxidative stress alters SIAH activity or its function in α-synuclein degradation.

In this study, SIAH-1 protein and mRNA expression levels were significantly increased in MPP^+^-treated cells. Hara et al. (2006) showed that 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment produces GAPDH/SIAH protein complexes in the corpus striatum, triggering the NO/GAPDH/SIAH cell death cascade. Furthermore, suppressing SIAH-1 markedly reduces cell death (Ortiz-Ortiz et al., 2010). These findings are consistent with our result that SIAH-1 antibody treatment increases cell viability in MPP^+^-treated cells. This suggests that the SIAH-1 antibody alleviates cellular stress. However, it remains unclear how the SIAH-1 antibody prevents the MPP^+^-induced reduction in cell viability.

Recent studies show that SIAH-1-mediated α-synuclein monoubiquitination leads to the formation of α-synuclein aggregates and inclusions (Rott et al., 2008; Szargel et al., 2009). SIAH-1 mediates the ubiquitination of α-synuclein at a single lysine, promoting aggregation and cytotoxicity (Engelender, 2008; Rott et al., 2008). Our results show that treatment with SIAH-1 antibody reduces α-synuclein levels in normal and MPP^+^-treated cells. In addition, our immunofluorescence results revealed that α-synuclein aggregates were significantly reduced as well by the antibody. However, the mechanisms by which SIAH-1 antibody reduces α-synuclein levels and plays a protective role in cells remain to be elucidated.

In summary, in this study, we found that MPP^+^ increases SIAH activity and impairs the clearance of α-synuclein by inducing the upregulation and aggregation of α-synuclein. Co-treatment with SIAH-1 antibody clearly had neuroprotective effects. Our findings suggest that SIAH-1 plays a key role in the pathogenesis of Parkinson\'s disease. Furthermore, SIAH-1 may be a potential new therapeutic target for neurodegenerative diseases characterized by α-synuclein aggregates.
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